Circulating tumor cells as promising novel biomarkers in solid cancers

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Circulating tumor cells (CTCs) are increasingly recognized as a valuable non-invasive "liquid biopsy" in cancer research.
• Their presence in peripheral blood offers insights into tumor biology, dissemination, and therapeutic resistance.
• CTCs are rare and challenging to isolate, demanding advanced analytical systems.

Purpose of the Study:

• To review the clinical potential of CTCs as biomarkers in 10 solid cancer types.
• To highlight the challenges and advancements in CTC detection, enumeration, and molecular characterization.
• To emphasize the utility of CTCs in monitoring patients and understanding metastasis.

Main Methods:

• Review of existing literature on CTC detection and analysis.
• Focus on CTCs in breast, ovarian, prostate, lung, colorectal, hepatocellular carcinoma, pancreatic, head and neck, bladder cancer, and melanoma.
• Discussion of analytical systems for CTC isolation and characterization.

Main Results:

• CTC detection and enumeration are FDA-cleared for metastatic breast, colorectal, and prostate cancer.
• CTC molecular characterization holds potential for understanding metastasis and therapy resistance.
• Ongoing research focuses on novel assays for single-CTC isolation and characterization.

Conclusions:

• CTCs represent a promising frontier in cancer research and clinical management.
• Their role as biomarkers is significant across a wide range of solid tumors.
• Advancements in isolation and characterization techniques are crucial for realizing their full clinical potential.